Angelman syndrome (AS) is a rare neurogenetic disorder that affects approximately one in 15,000 people – about 500,000 individuals worldwide. Symptoms include, but are not limited to: delayed developmental milestones; gross and fine motor impairment; difficulty with feeding and swallowing; issues; loss of functional speech and epilepsy.
FAST has a vision of a world where lives are no longer limited by a diagnosis of Angelman syndrome.
The mission of the Foundation for Angelman Syndrome Therapeutics Australia is to improve the quality of life for individuals with Angelman syndrome through timely diagnosis, access to best practices in care and treatments, and advancing research for a cure.
Founded in the United States, Australia is just one of the Global affiliates advancing Angelman syndrome research and clinical trials. FAST also has affiliates in Canada, France, Italy, Latin America (Argentina, Chile, Colombia), Spain and the UK.